Alerta

NLRP12 AND NLRC5 MODULATORS AND METHODS FOR USING THE SAME TO MODULATE DISEASES

Resumen de: US20260166125A1

Disclosed are compositions and methods for using heme and at least one PAMP and/or DAMP molecule for activating NLRP12 and/or NLRC5 and inflammatory cell death. Also provided is a screening assay for identifying NLRP12 and/or NLRC5 inhibitors and use of such inhibitors in the treating or ameliorating of NLRP12-mediated or NLRC5-mediated inflammation associated with a hemolytic disease, infectious disease, cancer, or inflammatory syndrome.

アルツハイマー病及び軽度認知障害のバイオマーカー及び治療

Resumen de: WO2021048619A2

The disclosure provides immunogenic peptides, compositions, means, and methods for treating Alzheimer's disease or mild cognitive impairment. The disclosure turther provides means and methods for diagnosing patients, selecting patients for treatment, and/or evaluating the efficacy of treatment for Alzheimer's disease or mild cognitive impairment

COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMORRHAGIC SHOCK

Resumen de: US20260166121A1

0000 Disclosed are methods of treating hemorrhagic shock, for example hemorrhagic shock associated with traumatic injury, gastrointestinal bleeding, spontaneous hemorrhage due to hematologic disorders, uterine hemorrhage, and combinations thereof, in an individual in need thereof. The methods may comprise administering a humanin protein or an analog thereof, for example Humanin G, to the individual.

METHOD FOR PREDICTING COLORECTAL CANCER PROGNOSIS USING MRNA OF HSPD1 GENE OR HSP60 PROTEIN ENCODED BY THESE GENES

Resumen de: US20260168029A1

The present invention relates to: a biomarker for predicting the prognosis of colorectal cancer by using changes in expression level of mRNA of a HSPD1 gene or a HSP60 protein encoded by these genes; and a prognosis prediction method using same. By analyzing the expression level of the HSPD1 gene or the HSP60 protein, the prognoses of colorectal cancer patients can be predicted in clinical practice, and when analysis is carried out in combination with TNM classification, more sophisticated prediction is possible and personalized strategies can be designed.

標的化剤

Resumen de: WO2023210585A1

The present invention provides a means for targeting a substance to motor nerve cells.　Provided is a targeting agent for a motor nerve cell synapse including an antibody that can bind to an in-vesicle domain of synaptotagmin 2.

INDUCED PROTEINOPATHY MODELS

Resumen de: US20260167928A1

Disclosed herein are methods and compositions useful in screening a compound for its effect on proteotoxicity and proteinaceous inclusions involved in neurological disease.

COMPOSITIONS CONTAINING CANNABINOID ANALOG CONJUGATES AND METHODS OF USE

Resumen de: US20260168979A1

0000 Embodiments of the disclosure provide a method of man-aging information related to a cannabis product across a distributed validated system. The method includes enabling an authorized user to create a plurality of data containing genetic profile of a seed, plant growth conditions of a crop, and manufacturing information used for production of the cannabis product, and measurements of quality and quantity of desired components and undesired components in the cannabis product. The method includes associating the plurality of data to a record which is identified by a unique identifier. The method includes storing the record into a memory for access by one or more of a plurality of authorized users using the unique identifier. The method includes analyzing the cannabis product to determine the quality and quantity of desired components and undesired components in the cannabis product. The method includes determining concentration of cannabinoids in the cannabis product.

NOVEL COMPOUNDS FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHIES

Resumen de: US20260167636A1

The present invention relates to compounds which are suitable for imaging TDP-43 (Transactive response (TAR) DNA binding protein 43 kDa) aggregates. The compounds can be used, for example, for diagnosing a disease, disorder or abnormality associated with TDP-43 aggregates or a TDP-43 proteinopathy, such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Frontotemporal dementia (FTD) and limbic-predominant age-related TDP-43 encephalopathy (LATE).

ASSAYS FOR DETECTING MTBR TAU

Resumen de: WO2026126161A2

Provided herein are methods and assays for detecting MTBR-243 tau peptides in biological samples, including blood-based samples from subjects, involving the use of a capture antibody that binds to a MTBR-tau 243 species, and a detection antibody. In some embodiments, the methods and assays include an immunodepletion step using one or more immunodepletion antibodies.

TARGETED THERAPY OF CANCER BY PHARMACOLOGICAL ACTIVATION OF MTOR

Resumen de: WO2026125700A1

The invention relates to the treatment of triple negative breast cancer (TNBC) with an activator of mTOR (Mammalian Target of Rapamycin). It has been found that migration of TNBC cells is significantly inhibited by an activation of mTOR, in particular of mTORC1, so that the early steps of metastasis, i.e. the migration in the microenvironment of the tumour, can be addressed in a targeted manner. The treatment according to the invention is preferably accompanied by chemotherapy or immunotherapy.

LIGHT CHAIN SPLIT LUCIFERASE (LSL) REPORTER SYSTEM AND ASSAY

Resumen de: WO2026128544A1

The present disclosure provides compositions and methods for determining the folding of a protein of interest. The present disclosure further provides methods for determining the pathogenicity of mutations in proteins.

METHODS AND SYSTEMS FOR ORGANELLE SCREENING

Resumen de: WO2026128913A1

Method are providing such as a method for detecting axon length in a neuronal cell culture that can be used for high throughput drug screening by culturing neuronal cells derived from a subject or an induced pluripotent stem cell line; imaging the neuronal cells to determine axon length; and correlating the axon length to a presence or severity of a neurological or metabolic disorder.

METHODS RELATED TO BIOLOGICAL AGE USING PROTEIN BIOMARKERS

Resumen de: US20260169009A1

The present invention comprises a method for determining the biological age of an animal, wherein the method comprises determining the level of at least one biomarker in said animal, and wherein the at least 1 biomarker is selected from the biomarkers as listed in Table 1.

難聴の予測または診断用組成物

Resumen de: WO2024258222A1

The present invention relates to: a composition and system for predicting or diagnosing hearing loss disorders, the composition including an agent for detecting point mutations in a plurality of genes or copy number variations; and an information provision method. In an aspect, the present invention comprises an agent capable of detecting: point mutations in a plurality of genes; or a copy number variation of at least one gene selected from the group consisting of STRC and TOOTA, thereby enabling simultaneous screening of a plurality of mutations on the basis of real-time PCR instead of NGS, thus having an excellent effect of predicting or diagnosing hearing loss in a short time at a low cost.

ANTI-A-BETA PROTEIN ANTIBODIES, METHODS AND USES THEREOF

Resumen de: WO2025032070A1

Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.

A HUMAN IPSC-DERIVED MODEL FOR TAUOPATHIES

Resumen de: WO2025031900A1

The present invention relates to a human ectoderm derived brain cell characterized by the following features: (1) the intron between exons 10 and 11 of the MAPT gene encoding the Tau protein has been removed by genome-editing from one or both allele(s); and (2) at least one of the alleles of the MAPT gene of (1) carries at least one mutation enhancing Tau aggregation and at least one mutation enhancing nucleation of Tau aggregation; or (3) one allele of the MAPT gene as defined in claim 1(1) carries at least one mutation enhancing Tau aggregation, preferably in exon 10, and the other allele carries at least one mutation enhancing nucleation of Tau aggregation, preferably in exon 11.

抗ＣＤ２４抗体およびその使用

Resumen de: WO2024251257A1

Provided are antibodies or fragments thereof having binding specificity to the human CD24 protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating cancer are also provided.

血液p-tau 217和GFAP标志物联用在制备阿尔茨海默病检测的辅助诊断试剂中的应用

Resumen de: CN122218240A

本申请涉及血液p‑tau 217和GFAP标志物联用在制备阿尔茨海默病检测的辅助诊断试剂中的应用。该应用中，利用p‑tau 217检测试剂检测待测样本中p‑tau 217的水平，利用GFAP检测试剂检测待测样本中GFAP的水平；当p‑tau 217检测项目和GFAP检测项目的检测水平与其对应参考水平的关系均满足设定条件时，判定为符合条件，不对受检者进行进一步的PET影像学检查或脑脊液检查；否则，对受检者进行进一步的PET影像学检查或脑脊液检查。本申请技术方案，能够提升AD的辅助排查检测的准确率，减少需要进一步做Aβ PET检查或脑脊液检查确证的患者比例，节约医疗资源，减少患者负担。

血浆蛋白质复合标志物及其在评估器官衰老程度中的方法和应用

Resumen de: CN122218242A

本发明提供了一组血浆蛋白质复合标志物在评估器官衰老程度中的方法和应用。具体地，本发明提供了蛋白质复合标志物在评估器官衰老程度和构建器官蛋白质时钟中的用途，以及评估器官衰老程度的方法；其中，所述蛋白质复合标志物共计使用494种血浆蛋白质，可同时评估全身、心血管、肝脏、免疫系统、代谢系统、肌肉骨骼、肺、肾脏、全脑、灰质、白质、功能性连接脑区的衰老状态。研究表明，利用本发明的蛋白质复合标志物进行器官衰老评估和患病风险预测的方法或系统准确性好且灵敏度高，具有大规模临床应用的前景。

一种基于碳点@共价有机框架的光阴极材料及其制备方法和应用

Resumen de: CN122213992A

0001 本发明涉及一种基于碳点@共价有机框架的光阴极材料及其制备方法和应用，属于光电化学生物传感器技术领域。一种基于碳点@共价有机框架的光阴极材料，所述光阴极材料为原位生长于导电基底上的CDs@T‑D‑COF薄膜，所述CDs@T‑D‑COF薄膜中碳点均匀分布于由TAPA与DHNDA缩合形成的COF孔道中。此外，本发明基于CDs@T‑D‑COF构建了一种可精准识别人血浆中痕量Aβ42的光电化学免疫传感器阵列，其在灵敏度、特异性和实用性方面均实现显著突破，尤其适用于复杂生物基质中极低浓度标志物的可靠检测，在临床转化应用中展现出广阔前景。

唾液TP17、TP47、TP15特异性抗体在制备神经梅毒辅助诊断产品中的应用

Resumen de: CN122218228A

0001 本发明涉及生物医药技术领域，具体公开了唾液TP17、TP47、TP15特异性抗体在制备神经梅毒辅助诊断产品中的应用。基于唾液中梅毒螺旋体特异性抗体免疫球蛋白G（IgG），包括唾液TP17/IgG、TP47/IgG和TP15/IgG的联合检测，输出受检者发生神经梅毒的风险值，或联合血清TRUST滴度构建四联合Logistic回归判别模型，基于预设判定阈值对受检者进行低风险或高风险分层，从而提高对神经梅毒的综合识别能力。本发明采用唾液作为检测样本，具有无创、便捷、易推广、可重复采集等优点，可用于神经梅毒的早期筛查、辅助诊断、及临床路径管理。

タウオパチー又はアミロイド形成疾患を検出するための血液ベースのアッセイ

Resumen de: WO2022013286A1

A method for detecting p217+tau in blood-based samples from a subject with high sensitivity, accuracy, and precision. The assay comprises contacting a sample with a capture antibody directed against a p217+tau epitope to bind the capture antibody to p217+tau peptides in plasma to form antibody-peptide complexes, and separately contacting the antibody-peptide complexes with a detection antibody to bind the detection antibody to the antibody-peptide complexes. The amount of p217+tau is determined by detecting the detection antibody. The amount of p217+tau detected is used to determine whether the subject has tauopathy or is at risk of developing tauopathy, or whether the subject has amyloidogenic disease or is at risk of developing amyloidogenic disease when the amount of p217+tau peptides is above a predetermined threshold value. The method has improved sensitivity such that the predetermined threshold value is above a Lower Limit of Quantification and/or Lower Limit of Detection of the assay.

一种分泌维生素B3单克隆抗体的杂交瘤细胞株及其应用

Resumen de: CN122214280A

本发明涉及一种分泌维生素B3单克隆抗体的杂交瘤细胞株及其应用，属于免疫检测技术领域。本发明经过多次筛选获得了一种能够分泌维生素B3单克隆抗体的杂交瘤细胞株，本发明的杂交瘤细胞株分泌的维生素B3单克隆抗体对维生素B3具有优异的亲和力和灵敏度，对维生素B3的IC50达到14.36 ng/mL，且对于维生素B3的结构类似物，例如维生素A、维生素K2、维生素K3、维生素K4、维生素E均无交叉反应。因此本发明的单克隆抗体可用于制备维生素B3的免疫检测产品，为维生素B3的残留检测提供高效的检测方法及手段。

具有Fc修饰的抗体和其使用方法

Resumen de: WO2025117965A1

The disclosure features anti-tumor necrosis factor receptor superfamily (TNFRSF), anti-tumor necrosis factor superfamily (TNFSF), anti-CD28, and anti-ICOS antibodies and antigen-binding fragments thereof with amino acid modifications at the Fc domain, and the use of these antibodies or antigen-binding fragments to modulate immune response. The antibodies and antigen-binding fragments thereof can be used to treat a wide variety of cancers, autoimmune disorders, neurological disorders, infectious diseases, inflammatory diseases, and transplant rejections.

脑微出血动物模型及其制备方法

Nº publicación: CN122228017A 16/06/2026

Solicitante:

亚乔大学校产学协力团

Resumen de: WO2025110434A1

The present application relates to a cerebral microbleed animal model in which cerebral microbleeds are induced by Col4a1-targeting guide RNA (gRNA) packed with AAV-BR1.